Eric Halioua
Company: PDC*line Pharma
Job title: President & Chief Executive Officer
Seminars:
Reporting Clinical Data from a First-in-Class Plasmacytoid Dendritic Cell Line Vaccine in Patients with Metastatic NSCLC 2:30 pm
Exploring the features and potential applications of the innovative PDC*vac technology as a novel cancer vaccine Unveiling new clinical safety and efficacy data from the most recent cohort of patients with NSCLC to support prior findings Using recent findings to direct future research and accelerate the treatment of patients with advanced solid tumorsRead more
day: Clinical Track Day One PM